septemb
total
laboratoryconfirm
case
infect
middl
east
respiratori
syndrom
coronaviru
merscov
report
world
health
organ
present
effect
specif
therapi
merscov
use
convalesc
plasma
cp
suggest
potenti
therapi
base
exist
evid
viral
infect
aim
studi
feasibl
cp
therapi
well
safeti
clinic
laboratori
effect
critic
ill
patient
merscov
infect
also
examin
pharmacokinet
merscov
antibodi
respons
viral
load
cours
merscov
infect
studi
inform
futur
random
control
trial
examin
efficaci
cp
therapi
merscov
infect
cp
collect
phase
potenti
donor
test
enzym
link
immunosorb
assay
elisa
indirect
fluoresc
antibodi
ifa
techniqu
presenc
antimerscov
antibodi
subject
antimerscov
ifa
titer
clinic
laboratori
evid
merscov
infect
screen
elig
plasma
donat
accord
standard
donat
criteria
cp
therapi
phase
consecut
critic
ill
patient
admit
intens
care
unit
laboratoryconfirm
merscov
infect
enrol
receiv
unit
cp
post
enrol
patient
follow
clinic
laboratori
outcom
includ
antimerscov
antibodi
viral
load
middl
east
respiratori
syndrom
coronaviru
merscov
initi
identifi
septemb
sampl
obtain
saudi
arabian
patient
develop
sever
acut
respiratori
infect
subsequ
acut
renal
failur
lead
death
zaki
et
al
septemb
total
case
identifi
relat
death
world
health
orgniz
date
specif
treatment
proven
effect
merscov
infect
public
health
england
intern
sever
acut
respiratori
emerg
infect
consortium
isar
publish
decis
support
tool
clinician
manag
case
merscov
infect
document
suggest
current
evid
strongest
test
convalesc
plasma
cp
therapeut
contain
neutral
antibodi
hyperimmun
immunoglobulin
treatment
seriou
merscov
ill
public
health
england
prior
experi
sar
sever
influenza
suggest
cp
may
consid
patient
deterior
despit
specif
support
therapi
viru
remain
detect
hung
et
al
luke
et
al
cheng
et
al
kong
zhou
yeh
et
al
recent
systemat
review
report
sar
sever
influenza
conclud
cp
therapi
appear
safe
may
reduc
mortal
especi
administ
earli
ill
mairjenkin
et
al
exploratori
post
hoc
metaanalysi
show
statist
signific
reduct
pool
odd
mortal
follow
treatment
compar
placebo
therapi
odd
ratio
confid
interv
mairjenkin
et
al
cite
case
seri
author
comment
patient
sever
present
appear
demonstr
tempor
clinic
improv
treatment
cp
administr
earli
possibl
diseas
cours
appear
associ
greatest
potenti
clinic
effect
one
random
clinic
trial
rct
critic
ill
influenza
infect
patient
found
surviv
benefit
hyperimmun
globulin
administ
within
day
symptom
onset
hung
et
al
howev
data
present
support
efficaci
cp
treatment
merscov
infect
therefor
recommend
administ
cp
context
clinic
trial
rct
requir
evalu
effect
evalu
effect
clinic
endpoint
mortal
like
requir
sever
hundr
sever
thousand
serious
ill
merscov
patient
order
achiev
suffici
statist
power
anticip
reason
potenti
effect
size
addit
cp
differ
merscov
survivor
like
contain
differ
level
neutral
antimerscov
antibodi
sinc
serious
ill
merscovinfect
patient
may
detect
viral
rna
variou
locat
sampl
exampl
lower
respiratori
tract
secret
prolong
period
might
possibl
first
determin
relationship
neutral
antibodi
dose
antivir
effect
clinic
laboratori
featur
small
openlabel
studi
inform
would
help
design
rct
determin
appropri
neutral
antibodi
dose
dose
rang
studi
may
also
inform
dose
select
followon
antimerscov
antibodi
prepar
current
preclin
develop
exampl
neutral
human
monoclon
antibodi
polyclon
human
neutral
immunoglobulin
deriv
transchromosom
cattl
person
commun
thoma
c
luke
therefor
plan
conduct
studi
first
phase
cp
collect
phase
explor
feasibl
collect
cp
donor
signific
titer
antimerscov
antibodi
second
phase
patient
merscov
infect
treat
cp
protocol
feasibl
safe
associ
tempor
chang
viral
load
ill
pilot
studi
inform
larger
conceal
intervent
placebocontrol
rct
power
evalu
efficaci
cp
relev
clinic
outcom
inclus
criteria
screen
potenti
cp
donor
includ
individu
follow
cohort
healthcar
worker
hcw
document
exposur
merscov
recov
patient
confirm
suspect
merscov
infect
household
contact
known
merscov
infect
patient
subject
will
donat
plasma
femal
prior
pregnanc
includ
donat
screen
consecut
critic
ill
patient
admit
intens
care
unit
area
hospit
critic
ill
patient
receiv
care
follow
criteria
inclus
criteria
critic
ill
defin
one
follow
admiss
icu
current
receipt
mechan
invas
noninvas
ventil
partial
pressur
oxygen
fraction
inspir
oxygen
ratio
mmhg
current
receipt
intraven
vasoact
medic
maintain
mean
arteri
pressur
mmhg
newonset
sinc
develop
merscov
symptom
receipt
renal
replac
therapi
extracorpor
life
support
laboratoryconfirm
merscov
infect
realtim
reversetranscript
polymeras
chain
reaction
rrtpcr
age
equal
year
symptomat
ill
exceed
two
week
day
time
enrol
neg
rrtpcr
respiratori
secret
blood
within
h
prior
assess
elig
histori
allerg
reaction
blood
plasma
product
judg
investig
known
iga
defici
medic
condit
receipt
ml
intravascular
volum
may
detriment
patient
eg
activ
decompens
congest
heart
failur
research
coordin
andor
physician
investig
explain
object
studi
potenti
risk
benefit
donor
patient
hisher
surrog
decis
maker
obtain
follow
consent
form
appropri
cp
collect
phase
consent
merscov
serolog
test
merscov
rtpcr
donor
consent
cp
donat
elev
antimerscov
titer
describ
cp
therapi
phase
consent
enrol
cp
therapi
phase
consent
enrol
observ
studi
intervent
receiv
particip
still
blood
possibl
respiratori
sampl
takenfor
particip
receiv
intervent
cp
collect
phase
elig
candid
cp
donat
per
inclus
exclus
criteria
approach
blood
test
antimerscov
serolog
see
laboratori
method
subject
seroposit
screen
subsequ
merscov
rrtpcr
exclud
activ
infect
critic
ill
merscov
patient
meet
patient
elig
criteria
approach
consent
patient
blood
type
determin
cp
must
abo
compat
recipi
blood
type
trial
intervent
includ
administr
unit
cp
unit
plasma
given
h
interv
h
two
unit
plasma
transfus
done
accord
standard
polici
administr
blood
product
clinic
team
full
independ
control
patient
manag
manag
cp
therapi
influenc
intervent
studi
team
cointervent
includ
corticosteroid
ribavirin
intraven
immunoglobulin
interferon
document
studi
case
report
form
coenrol
anoth
studi
permiss
long
enrol
studi
would
moder
high
risk
biolog
analyt
confound
result
studi
judg
studi
manag
committe
per
publish
guidelin
clinic
laboratori
data
collect
baselin
min
first
dose
min
second
dose
studi
day
explor
feasibl
studi
intervent
measur
abil
screen
potenti
plasma
donor
deriv
suffici
plasma
enrol
patient
month
period
also
qualit
describ
logist
challeng
experienc
conduct
studi
includ
ethic
administr
regulatori
challeng
establish
safeti
studi
intervent
measur
number
seriou
advers
event
relat
studi
intervent
advers
event
includ
develop
complic
intravascular
volum
overload
clinic
pulmonari
edema
tempor
relatedshort
breath
chest
radiograph
find
chang
oxygen
requir
develop
transfusionrel
acut
lung
injuri
trali
substanti
allergi
anaphylaxi
seriou
event
adjud
committe
investig
clinic
outcom
measur
sequenti
organ
failur
assess
sofa
score
studi
day
requir
organ
support
oxygen
ventil
dialysi
vasopressor
enrol
length
stay
icu
defin
number
calendar
day
admiss
final
discharg
icu
icu
admiss
enrol
durat
mechan
ventil
defin
number
calendar
day
start
final
liber
mechan
ventil
icu
admiss
enrol
hospit
length
stay
defin
number
calendar
day
admiss
hospit
final
discharg
hospit
hospit
admiss
vital
outcom
mortal
icu
hospit
day
clinic
outcom
includ
icufre
day
defin
number
day
patient
icu
first
day
enrol
patient
die
within
day
count
separ
categoris
icufre
day
similarli
ventilatorfre
day
defin
number
day
patient
receiv
mechan
ventil
first
day
enrol
renal
replac
therapyfre
day
vasopressorfre
day
defin
similar
way
serial
chest
radiograph
find
obtain
clinic
team
also
record
per
case
report
form
grade
unilater
bilater
infiltr
quadrant
laboratori
outcom
measur
follow
laboratori
outcom
serum
level
antimerscov
antibodi
administr
cp
b
merscov
viral
load
primari
laboratori
outcom
viral
clearanc
sampl
site
day
administr
cp
merscov
antibodi
test
first
enzym
link
immunosorb
assay
elisa
screen
test
drosten
et
al
et
al
accord
manufactur
instruct
euroimmun
ag
germani
result
report
optic
densiti
od
ratio
calcul
od
valu
patient
sampl
divid
calibr
od
valu
use
cutoff
valu
recommend
manufactur
ratio
consid
neg
borderlin
ratio
consid
posit
confirm
done
indirect
fluoresc
antibodi
ifa
euroimmun
ag
germani
accord
manufactur
instruct
sampl
consid
reactiv
accord
manufactur
instruct
subject
consid
candid
plasma
donat
titer
similar
threshold
use
convalesc
plasma
trial
influenza
hung
et
al
primari
coordin
studi
center
intens
care
depart
king
saud
bin
abdulaziz
univers
health
scienc
ksauh
riyadh
saudi
arabia
studi
conduct
accord
ethic
principl
declar
helsinki
intern
confer
harmonizationgood
clinic
practic
ichgcp
guidelin
sever
measur
taken
ensur
optim
complianc
studi
protocol
launch
studi
icu
physician
nurs
attend
train
session
special
emphasi
advers
event
note
intervent
steer
committe
led
princip
investig
respons
overse
conduct
trial
uphold
modifi
studi
procedur
need
address
challeng
protocol
implement
formul
analysi
plan
review
interpret
data
prepar
manuscript
studi
also
independ
data
safeti
monitor
board
dsmb
respons
review
report
submit
regard
safeti
studi
patient
protocol
adher
may
make
recommend
continu
termin
studi
base
safeti
analysi
result
dsmb
compos
member
name
end
document
meet
begin
phase
ii
studi
follow
need
event
acut
transfus
reaction
transfus
stop
immedi
must
report
blood
bank
princip
investig
immedi
well
studi
manag
committe
seriou
advers
event
sae
adjud
relat
studi
intervent
report
institut
research
ethic
board
dsmb
exploratori
studi
aim
rectifi
current
lack
inform
use
cp
treat
merscov
infect
due
exploratori
natur
studi
pauciti
sequenti
data
viral
rna
level
respiratori
tract
blood
sampl
merscovinfect
patient
clinic
progress
sampl
size
fix
realist
target
studi
month
durat
sampl
size
suffici
reach
conclus
surviv
rate
significantli
exce
p
patient
surviv
day
followup
would
repres
promis
evid
motiv
fullscal
compar
clinic
trial
serial
merscov
viral
load
measur
display
box
whisker
plot
treat
patient
time
probabl
patient
undetect
viral
load
sampl
site
day
administr
therapi
estim
proport
treat
patient
occur
exact
conserv
twosid
confid
interv
probabl
calcul
use
method
clopper
pearson
relationship
log
viral
load
day
neutral
antibodi
dose
receiv
characteris
fit
regress
model
data
treat
patient
log
viral
load
baselin
includ
model
relationship
probabl
patient
undetect
viral
load
day
neutral
antibodi
dose
receiv
characteris
fit
loglogist
regress
model
data
treat
patient
log
viral
load
baselin
includ
model
sofa
score
indic
whether
patient
requir
organ
support
via
oxygen
ventil
dialysi
vasopressor
plot
time
relationship
sofa
score
day
neutral
antibodi
dose
receiv
receipt
type
organ
support
day
observ
neutral
antibodi
dose
receiv
characteris
fit
logist
regress
model
data
treat
patient
log
viral
load
baselin
includ
model
vital
statu
aliv
dead
patient
record
day
proport
aliv
plot
time
relationship
hazard
death
neutral
antibodi
dose
receiv
characteris
fit
cox
proport
hazard
regress
model
data
treat
patient
log
viral
load
baselin
includ
model
probabl
patient
die
day
estim
proport
treat
patient
occur
exact
conserv
twosid
confid
interv
probabl
calcul
use
method
clopper
pearson
time
infectionexposur
sampl
collect
day
durat
infectionexposur
cp
therapi
length
stay
icu
number
icufre
day
durat
mechan
ventil
number
ventilatorfre
day
renal
replac
therapyfre
day
vasopressorfre
day
length
stay
hospit
present
histogram
suitabl
summari
statist
comput
conduct
exploratori
stratifi
analy
base
time
symptom
onset
cp
therapi
initi
comorbid
cointervent
baselin
sever
sofa
score
treatment
initi
sa
system
window
version
sa
institut
inc
cari
north
carolina
r
use
analys
protocol
develop
collabor
king
abdullah
intern
medic
research
center
kaimrc
gulf
cooper
council
gcc
infect
control
center
group
world
health
organizationintern
sever
acut
respiratori
emerg
infect
consortium
isaricwho
merscov
work
group
approv
ministri
nation
guard
health
affair
institut
review
board
irb
approv
number
june
regist
clinicaltrialsgov
proven
effect
cp
therapi
attract
therapeut
option
merscov
infect
besid
biolog
plausibl
therapi
easi
obtain
administ
rel
inexpens
like
accept
patient
treat
team
side
effect
unlik
differ
transfus
fresh
frozen
plasma
believ
studi
protocol
set
stage
larg
efficaci
trial
strength
weak
studi
protocol
note
cp
collect
phase
subject
enrol
differ
cohort
order
explor
potenti
donor
unknown
point
subject
like
high
antibodi
titer
therefor
cp
donor
hope
feasibl
studi
help
identifi
group
superdonor
high
titer
identifi
characterist
individu
focus
approach
donat
follow
cp
therapi
phase
design
establish
efficaci
object
requir
adequ
power
random
control
trial
howev
believ
perform
feasibl
studi
essenti
step
examin
safeti
clinic
laboratori
effect
pharmacokinet
merscov
antibodi
respons
studi
involv
give
critic
ill
patient
therapi
control
monitor
set
howev
recent
systemat
review
suggest
earli
treatment
cp
like
effect
late
treatment
mairjenkin
et
al
therefor
feasibl
studi
show
cp
safe
feasibl
next
step
random
control
trial
suffici
power
detect
effect
mortal
enrol
patient
earli
cours
diseas
studi
anticip
provid
inform
feasibl
collect
convalesc
plasma
larg
quantiti
therapeut
use
larg
number
merscov
patient
data
anticip
inform
relat
antibodi
titer
cp
viral
clearanc
laboratori
clinic
endpoint
data
critic
plan
larger
rct
examin
efficaci
cp
patient
merscov
infect
